Innovent Biologics's EPS (Basic) for the
six
months ended in Dec. 2023 was HK$-0.62.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.72.
During the past 3 years, the average EPS without NRIGrowth Rate was 6.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 35.60% per year.
During the past 8 years, Innovent Biologics's highest 3-Year average EPS without NRI Growth Rate was 50.50% per year. The lowest was -45.90% per year. And the median was -0.10% per year.
Innovent Biologics Earnings per Share (Diluted) Historical Data
The historical data trend for Innovent Biologics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Innovent Biologics Earnings per Share (Diluted) Chart
Competitive Comparison of Innovent Biologics's Earnings per Share (Diluted)
For the Biotechnology subindustry, Innovent Biologics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's PE Ratio falls into.
Innovent Biologics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Innovent Biologics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.72
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Innovent Biologics (HKSE:01801) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Innovent Biologics Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of Innovent Biologics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Innovent Biologics (HKSE:01801) Business Description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01801 has been successfully added to your 